Cargando…

Crizotinib: A comprehensive review

Anaplastic lymphoma kinase (ALK) gene rearrangements are present in a small subset of non-small-cell lung cancers. ALK-positivity confers sensitivity to small-molecule ALK kinase inhibitors, such as crizotinib. The integration of crizotinib into standard treatment practice in NSCLC will rest on the...

Descripción completa

Detalles Bibliográficos
Autores principales: Sahu, Arvind, Prabhash, Kumar, Noronha, Vanita, Joshi, Amit, Desai, Saral
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3876666/
https://www.ncbi.nlm.nih.gov/pubmed/24455567
http://dx.doi.org/10.4103/2278-330X.110506
_version_ 1782297530090913792
author Sahu, Arvind
Prabhash, Kumar
Noronha, Vanita
Joshi, Amit
Desai, Saral
author_facet Sahu, Arvind
Prabhash, Kumar
Noronha, Vanita
Joshi, Amit
Desai, Saral
author_sort Sahu, Arvind
collection PubMed
description Anaplastic lymphoma kinase (ALK) gene rearrangements are present in a small subset of non-small-cell lung cancers. ALK-positivity confers sensitivity to small-molecule ALK kinase inhibitors, such as crizotinib. The integration of crizotinib into standard treatment practice in NSCLC will rest on the widespread implementation of an effective screening system for newly diagnosed patients with NSCLC which is flexible enough to incorporate new targets as treatments are developed for them. Phase I and II studies of crizotinib in ALK-positive lung cancer have demonstrated significant activity and impressive clinical benefit, which led to its early approval by USFDA in 2011. Although crizotinib induces remissions and extends the lives of patients, there have been reports of emerging resistance to Crizotinib therapy. In this review, we discuss the history, mechanism of action, uses, adverse effects, dose modifications and future challenges and opportunities for patients with ALK-positive lung cancers.
format Online
Article
Text
id pubmed-3876666
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-38766662014-01-16 Crizotinib: A comprehensive review Sahu, Arvind Prabhash, Kumar Noronha, Vanita Joshi, Amit Desai, Saral South Asian J Cancer Drug Review Anaplastic lymphoma kinase (ALK) gene rearrangements are present in a small subset of non-small-cell lung cancers. ALK-positivity confers sensitivity to small-molecule ALK kinase inhibitors, such as crizotinib. The integration of crizotinib into standard treatment practice in NSCLC will rest on the widespread implementation of an effective screening system for newly diagnosed patients with NSCLC which is flexible enough to incorporate new targets as treatments are developed for them. Phase I and II studies of crizotinib in ALK-positive lung cancer have demonstrated significant activity and impressive clinical benefit, which led to its early approval by USFDA in 2011. Although crizotinib induces remissions and extends the lives of patients, there have been reports of emerging resistance to Crizotinib therapy. In this review, we discuss the history, mechanism of action, uses, adverse effects, dose modifications and future challenges and opportunities for patients with ALK-positive lung cancers. Medknow Publications & Media Pvt Ltd 2013 /pmc/articles/PMC3876666/ /pubmed/24455567 http://dx.doi.org/10.4103/2278-330X.110506 Text en Copyright: © South Asian Journal of Cancer http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Drug Review
Sahu, Arvind
Prabhash, Kumar
Noronha, Vanita
Joshi, Amit
Desai, Saral
Crizotinib: A comprehensive review
title Crizotinib: A comprehensive review
title_full Crizotinib: A comprehensive review
title_fullStr Crizotinib: A comprehensive review
title_full_unstemmed Crizotinib: A comprehensive review
title_short Crizotinib: A comprehensive review
title_sort crizotinib: a comprehensive review
topic Drug Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3876666/
https://www.ncbi.nlm.nih.gov/pubmed/24455567
http://dx.doi.org/10.4103/2278-330X.110506
work_keys_str_mv AT sahuarvind crizotinibacomprehensivereview
AT prabhashkumar crizotinibacomprehensivereview
AT noronhavanita crizotinibacomprehensivereview
AT joshiamit crizotinibacomprehensivereview
AT desaisaral crizotinibacomprehensivereview